Forte Biosciences Q3 net loss per share improves

Forte Biosciences reported an improved Q3 2025 net loss per share compared to 2024, despite increased R&D expenses due to expanded clinical trials for FB102. The company anticipates significant clinical trial readouts in 2026, viewing it as pivotal for FB102's market potential. Analysts rate the stock as a 'buy,' with a 12-month price target of $57.50, significantly above its current price. The report was generated using Reuters automation and AI.

)

Overview

Forte Biosciences Q3 2025 net loss per share decreased compared to the same period in 2024
Research and development expenses rose due to increased clinical trial activities
Company expects three clinical trial readouts for FB102 in 2026

Outlook

Forte expects three clinical trial readouts for FB102 in 2026
Company anticipates topline data for celiac disease trial in 2026
Forte sees 2026 as pivotal for FB102’s market potential

Result Drivers

CLINICAL TRIAL EXPANSION - Increased R&D expenses driven by expanded clinical trials for FB102 in celiac disease, vitiligo, and alopecia areata

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$17.68

Income mln

Q3 Basic -$0.99

EPS

Q3 -$18.38

Income mln

From

Operatio

Q3 $18.38

Operatin mln

Expenses

Analyst Coverage

The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 5 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
The average consensus recommendation for the biotechnology & medical research peer group is “buy”
Wall Street’s median 12-month price target for Forte Biosciences Inc is $57.50, about 75.9% above its November 13 closing price of $13.84

Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)